Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension
| Autor: | J. Bahena, J.J. De La Fuente, P. Fernandez-Bonetti, E. Campos, L. Alcocer, R. Dominguez-Henkel, R. Olvera Ruiz, C. Segovia-Ayala |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Supine position business.industry medicine.drug_class General Medicine Atenolol Essential hypertension medicine.disease Angiotensin II law.invention Blood pressure Endocrinology Randomized controlled trial law Internal medicine Anesthesia Medicine cardiovascular diseases Telmisartan business Beta blocker circulatory and respiratory physiology medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 58:35-39 |
| ISSN: | 1368-5031 |
| DOI: | 10.1111/j.1742-1241.2004.00408.x |
| Popis: | The objective of this open-label, parallel-group comparative study was to assess the clinical efficacy and safety of once-daily treatment for 8 weeks with telmisartan 80 mg in comparison with atenolol 50 mg on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in patients with mild-to-moderate hypertension (morning supine SBP 141-199 mmHg, DBP 95-114 mmHg). A total of 58 patients were enrolled. The comparability of the two treatment groups was statistically documented at the beginning of the study. Telmisartan was more effective than atenolol, with a decrease in SBP of 21.7 mmHg vs. 11.8 mmHg (p = 0.03) and a non-significant decrease in DBP of 14.7 mmHg vs. 10.1 mmHg. The safety profiles of both drugs were very similar; both drugs were well tolerated. In conclusion, once-daily telmisartan 80 mg is more effective than once-daily atenolol 50 mg in lowering SBP with no negative chronotropism. Furthermore, telmisartan was as well tolerated as atenolol in the treatment of mild-to-moderate essential hypertension in adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|